NCT06904196 2025-04-29
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
Clinical Trials
11 trialsNCT02936388 2025-01-24
SirTac
Charite University, Berlin, Germany
Phase 2 Completed
NCT05992584 2023-09-14
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT05994859 2023-09-14
SIRT for Potentially Resectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Phase NA Recruiting
NCT04332419 2022-06-22
Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies
Case Comprehensive Cancer Center
Phase NA Completed
NCT01126645 2019-05-31
SORAMIC
University of Magdeburg
Phase 2 Completed
NCT03910140 2019-04-10
TILA-TACE in Treatment of Hepatocellular Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Unknown
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT01798147 2017-05-23
Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).
Johannes Gutenberg University Mainz
Phase 2 Unknown
NCT01798160 2015-10-20
Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).
Johannes Gutenberg University Mainz
Phase 4 Completed
NCT00604409 2015-09-07
Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer
Fox Chase Cancer Center
Phase 1 Completed